XML 18 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenues [Abstract]      
Revenue $ 178,957 $ 170,276 $ 185,308
Operating expenses      
Cost of revenue 72,080 75,553 57,909
Research and development 102,953 122,117 141,756
Sales and marketing 84,759 88,579 95,603
General and administrative 72,806 83,934 88,527
Amortization of intangible assets 1,703 1,699 1,699
Impairment of long-lived assets 7,205 [1],[2] 25,429  
Total operating expenses 341,506 397,311 385,494
Loss from operations (162,549) (227,035) (200,186)
Interest and other income, net [1] 14,534 15,531 4,056
Interest expense [1],[3] (11,580) (13,800) (4,238)
Net loss (159,595) (225,304) (200,368)
Add: Net loss attributable to noncontrolling interest [1] 103 54 177
Net loss attributable to Adaptive Biotechnologies Corporation [1] $ (159,492) $ (225,250) $ (200,191)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic $ (1.08) $ (1.56) $ (1.4)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic 147,101,648 144,383,294 142,515,917
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted $ (1.08) $ (1.56) $ (1.4)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted 147,101,648 144,383,294 142,515,917
[1] Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.
[2] Represents expenses recognized in conjunction with restructuring activities. See Note 15, Restructurings for details on our restructuring expenses.
[3] Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, Revenue Interest Purchase Agreement for details on the Purchase Agreement.